2006

• 20 December 2006 - MorphoSys and Schering-Plough Sign R&D Agreement
• 11 December 2006 - Nuvelo and Bayer Healthcare Announce Phase 3 Trials of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion and Catheter Occlusion Did Not Meet Primary Endpoints
• 8 December 2006 - GTx Announces That Ostarine Achieved Primary Endpoint of Lean Body Mass and a Secondary Endpoint of Improved Functional Performance in a Phase II Clinical Trial and Reacquisition of Full Rights to GTx SARM Program 
• 6 December 2006 - ProStrakan announces positive results from pivotal Phase III study on Sancuso™ (transdermal granisetron patch)
• 14 November 2006 - Acambis: Update on US Government MVA procurement
• 13 November 2006 - Illumina Signs Definitive Agreement to Acquire Solexa
• 9 November 2006 - Genentech Announces Agreement to Acquire Tanox for $20 Per Share
• 6 November 2006 - Adolor – FDA Issues Approvable Letter for Entereg(R) (alvimopan) for POI
• 26 October 2006 - Achillion Pharmaceuticals Announces Pricing of Its Initial Public Offering
• 9 October 2006 - Pfizer Expands Commitment to Fight Infectious Diseases with Agreement to Acquire Vaccine Company Powdermed Ltd 
• 2 October 2006 - Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion
• 24 September 2006 - GPC Biotech and Pharmion Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint
• 21 September 2006 - Jerini Announces Positive Results from Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema
• 20 September 2006 - Alexion: Soliris™ (eculizumab) Demonstrates Significant Improvement in PNH Study -Phase III TRIUMPH Study Published in New England Journal of Medicine
• 5 September 2006 - GlaxoSmithKline and Adolor Report Top-Line Results From Phase 3 Studies of Alvimopan (Entereg/Entrareg(R)
• 30 August 2006 - Genzyme to Initiate Tender Offer to Acquire AnorMED Inc
• 2 August 2006 - ESBATech Closes CHF 50M (USD 41M) Series B Venture Financing 
• 25 July 2006 - Momenta Pharmaceuticals and Sandoz Sign Exclusive Collaboration to Develop Complex Generics and Follow-On Versions of Biotechnology Drugs
• 12 July 2006 - Gilead: U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection 
• 9 June 2006 - CSL Limited Announces FDA Approval of its Licensee Merck & Co Inc's Cervical Cancer Vaccine GARDASIL 
• 5 June 2006 - GTx Announces ASCO Presentation of Phase III Interim Analysis Showing ACAPODENE Increased Bone Mineral Density in Prostate Cancer Patients on Androgen Deprivation Therapy
• 31 May 2006 - Adolor's Complete Response to Approvable Letter for Entereg(R) (Alvimopan) in POI Accepted for Review by FDA; FDA Performance Goal Date is Targeted for November 2006
• 17 May 2006 - MorphoSys Enlarges Therapeutic Antibody Collaboration with Pfizer - Expansion Doubles Potential Deal Volume for MorphoSys
• 15 May 2006 - AstraZeneca's recommended offer for Cambridge Antibody Technology
• 9 May 2006 - Merck & Co., Inc. to Acquire GlycoFi, Inc.
• 3 May 2006 - MGI Pharma: U.S. FDA Approves Dacogen(TM) (Decitabine) for Injection; Dacogen(TM) Approved for Patients with all FAB Classifications of MDS; Commercial Launch Planned For Late May

2005

• 23 December 2005 - Acquisition Of KuDOS Pharmaceuticals Will Enhance AstraZeneca’s Ability To Generate Novel Cancer Treatments